PT - JOURNAL ARTICLE AU - Mayer, Annalina V. AU - Preckel, Katrin AU - Ihle, Kristin AU - Piecha, Fabian A. AU - Junghanns, Klaus AU - Reiche, Stefan AU - Rademacher, Lena AU - Kamp-Becker, Inge AU - Stroth, Sanna AU - Roepke, Stefan AU - Küpper, Charlotte AU - Engert, Veronika AU - Singer, Tania AU - Kanske, Philipp AU - Paulus, Frieder M. AU - Krach, Sören TI - No support for oxytocin modulation of reward-related brain function in autism: evidence from a randomized controlled trial AID - 10.1101/2021.03.19.21253900 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.19.21253900 4099 - http://medrxiv.org/content/early/2021/03/23/2021.03.19.21253900.short 4100 - http://medrxiv.org/content/early/2021/03/23/2021.03.19.21253900.full AB - Autism spectrum disorder (ASD) is characterized by difficulties in social communication and interaction, which have been related to atypical neural processing of rewards, especially in the social domain. Since intranasal oxytocin has been shown to modulate activation of the brain’s reward circuit, oxytocin could be a useful tool to ameliorate the processing of social rewards in ASD and thus improve social difficulties. In this randomized, double-blind, placebo-controlled, crossover fMRI study, we examined effects of a 24 IU dose of intranasal oxytocin on reward-related brain function in 37 men with an ASD diagnosis and 37 age- and IQ-matched control participants. Participants performed an incentive delay task that allows the investigation of neural activity associated with the anticipation and receipt of monetary and social rewards. Apart from a specific interaction effect in a single voxel within the left amygdala during the receipt of rewards, oxytocin did not influence neural processes related to the anticipation or consumption of social or monetary rewards in either group. Exploratory analyses suggested that oxytocin may increase ventral striatum sensitivity to monetary, but not social rewards, in individuals with high levels of self-reported anxiety, depression, alexithymia, and autistic traits irrespective of an ASD diagnosis. There were no significant differences in reward-related brain function between the two groups under placebo. Overall, our results do not support the hypothesis that intranasal oxytocin generally enhances activation of reward-related neural circuits in men with and without ASD without intellectual impairment. How and if oxytocin can be beneficial in the treatment of social difficulties in ASD needs to be addressed by examining moderating influences of individual differences and context on reward-related oxytocin effects.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00010053Clinical Protocols http://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-016-1036-x Funding StatementThis clinical trial was part of the ASD-Net, the German consortium for Autism Spectrum Disorder, and was funded by the German Federal Ministry of Education and Research (BMBF, grant numbers: 01EE1409H and 01EE1409I). Funding period: 2015-2019. Parts of the study were performed, and MRI data were assessed at the former department of Social Neuroscience at the Max Planck Institute for Human Cognitive and Brain Sciences Leipzig (MPI-CBS) headed by Prof. Dr. Tania Singer until 2018. Funding required for neuroimaging, the support team (e.g., technical, imaging, physician, recruitment) and some of the researchers (Kanske, Engert) during that period was provided by Tania Singer's budget she received as director of the department of Social Neuroscience by the Max Planck Society.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:German Federal Institute for Drugs and Medical Devices (Bundesinstitut fur Arzneimittel und Medizinprodukte; BfArM; Gz: 61-3910-4041063) Ethics Committee of the University of Lubeck, Germany (AZ 15-337)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and analyzed during the current study are not publicly available due to them containing information that could compromise research participant privacy and consent. Fully anonymized data are available from the corresponding author on reasonable request.